University of North Carolina Chapel Hill Physician Office Building
Welcome,         Profile    Billing    Logout  
 1 Trial 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grilley-Olson, Juneko
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
A091902, NCT04339738: Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

Active, not recruiting
2
90
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
09/25
09/25
Frigault, Matthew J
NCT06550141: Emapalumab Prevention of CAR-T Cell Associated Toxicities

Recruiting
2
28
US
Emapalumab, Human anti-interferon gamma (IFNγ) monoclonal antibody, Gamifant, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel
Marcela V. Maus, M.D.,Ph.D., Swedish Orphan Biovitrum
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
08/26
08/27
NCT05952804: IVIG for Infection Prevention After CAR-T-Cell Therapy

Recruiting
2
150
US
Immune Globulin Infusion (Human), 10% Solution, GAMMAGARD LIQUID, Anti-CD19 CAR T Cells Preparation, CD19-targeting CAR-T Cells, Saline, 7647-14-5, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Survey Administration, Electronic Health Record Review
Fred Hutchinson Cancer Center, Takeda, National Cancer Institute (NCI)
Lymphoma
07/27
07/28
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated
1/2
13
US
GDA-201, NAM NK
Gamida Cell ltd
Non-Hodgkin Lymphoma
04/24
04/24
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
NCT04134117: Tisagenlecleucel in Primary CNS Lymphoma

Completed
1
6
US
Tisagenlecleucel, KYMRIAH
Matthew J. Frigault, M.D., Novartis
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
04/22
04/22
NCT04136275: CAR-37 T Cells in Hematologic Malignancies

Completed
1
6
US
CAR-37 T cells
Marcela V. Maus, M.D.,Ph.D.
Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
09/23
03/24
NCT05020444: TriPRIL CAR T Cells in Multiple Myeloma

Recruiting
1
18
US
TriPRIL CAR T Cells, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludara
Marcela V. Maus, M.D.,Ph.D.
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
01/26
01/28
ARC-101, NCT04155749: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Active, not recruiting
1
40
US
anitocabtagene-autoleucel
Kite, A Gilead Company, Arcellx, Inc.
Relapsed and Refractory Multiple Myeloma
08/24
11/35
NCT06026319: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Recruiting
1
24
US
CD79b-19 CAR T cells, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludara
Marcela V. Maus, M.D.,Ph.D.
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma
01/27
01/28
NCT04473937: Radiation Post-CAR T in Refractory Lymphoma

Terminated
N/A
3
US
Radiotherapy
Massachusetts General Hospital
Hematologic Malignancy, Refractory Lymphoma
10/21
07/23
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT05024175: Long-term Follow-up of Subjects Treated with CAR T Cells

Recruiting
N/A
45
US
Disease assessments, Tumor Biopsy, Blood test
Massachusetts General Hospital
Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
08/38
08/39

Download Options